Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

49.08
-1.1500-2.29%
Post-market: 48.90-0.1800-0.37%19:32 EDT
Volume:1.49M
Turnover:73.66M
Market Cap:9.38B
PE:-11.99
High:50.73
Open:50.61
Low:48.84
Close:50.23
52wk High:51.86
52wk Low:21.72
Shares:191.17M
Float Shares:151.20M
Volume Ratio:0.69
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0935
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-41.96%
PB:-5.25
PE(LYR):-17.05

Loading ...

BridgeBio Pharma Inc. Publishes Document on CLARIFY Study of ADH1/2 Disease Monitoring

Reuters
·
Jul 15

Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Jul 14

U.S. RESEARCH ROUNDUP-Best Buy, Chevron, SoundHound AI

Reuters
·
Jul 14

BridgeBio Pharma Inc. Publishes Document on Phase 2/3 Study of Encaleret for Autosomal Dominant Hypocalcemia Type 1 in Pediatrics

Reuters
·
Jul 14

BridgeBio Pharma Inc. Publishes Findings on Genetic Contributors of Non-Surgical Hypoparathyroidism

Reuters
·
Jul 13

BridgeBio Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Jul 12

BridgeBio price target raised to $67 from $58 at Citi

TIPRANKS
·
Jul 11

BridgeBio Pharma May Keep Outperforming as Attruby Sales Beat Consensus, Oppenheimer Says

MT Newswires Live
·
Jul 09

High Growth Tech Stocks To Watch In The US July 2025

Simply Wall St.
·
Jul 08

BridgeBio Pharma CEO Neil Kumar Reports Disposal of Common Shares

Reuters
·
Jul 04

BridgeBio Pharma Inc. Enters $300 Million Royalty Financing Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP

Reuters
·
Jul 02

Director Hannah Valantine Reports Disposal of Common Shares in BridgeBio Pharma Inc

Reuters
·
Jul 01

BridgeBio Pharma (BBIO) Receives a Buy from Citi

TIPRANKS
·
Jul 01

BridgeBio Pharma Expands European Presence with $300 Million Royalty Monetization Deal for BEYONTTRA

Reuters
·
Jun 30

Director Frank McCormick Reports Disposal of Common Shares of BridgeBio Pharma Inc

Reuters
·
Jun 27

BridgeBio Pharma Announces Upcoming Investor Webinar to Discuss Progress of LGMD2I/R9 Program and Phase 3 Trial Expectations

Reuters
·
Jun 26